// App-Quantinova.ai

6004.0 : Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-agnostic ovarian cancer.

Researchers

Presenter

  • Lucy Gilbert

Principal Investigators

  • Ana Oaknin

  • Ursula A. Matulonis

  • Gina Mantia-Smaldone

  • Peter C Lim

  • Cesar Martin Castro

  • Diane M. Provencher

  • Sanaz Memarzadeh

  • Jiuzhou Wang

  • Brooke Esteves

  • Patrick A Zweidler-McKay

  • Kathleen N. Moore

  • David M. O'Malley

Medical Centers

  • McGill University - Royal Victoria Hospital, Montreal, QC, Canada

  • Vall d Hebron University Hospital (HUVH) and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

  • Dana-Farber Cancer Institute, Boston, MA

  • Fox Chase Cancer Center, Philadelphia, PA

  • Center of Hope at Renown Regional Medical Center, Reno, NE

  • Massachusetts General Hospital/Harvard Medical School, Reading, MA

  • University of Montreal, Montreal, QC, Canada

  • University of California, Los Angeles, Los Angeles, CA

  • Immunogen, Waltham, MA

  • Kadmon Rsrch Inst, Wilmington, MA

  • Immunogen, Waltham, MA

  • University of Oklahoma Health Sciences Center, Oklahoma City, OK

  • The Ohio State University College of Medicine, Columbus, OH

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Genetic Disorder

Disease

  • N/A

Biomarkers

  • Folate Receptor 1

  • Apparent diffusion coefficient

Drug/Treatment

  • Mirvetuximab

  • Bevacizumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT02606305

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved